Drug Profile

Indium 111-radiolabelled OTSA 101 - OncoTherapy Science

Alternative Names: OTSA 101 DTPA-111In

Latest Information Update: 16 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator OncoTherapy Science
Class Antineoplastics; Immunoconjugates; Immunotherapies; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

11 Jan 2024 OncoTherapy Science terminates a phase I trials for Synovial-sarcoma (Refractory metastatic disease, Second-line therapy or greater) in Japan (IV, Injection), due to some of the raw materials for the investigational drug are difficult to obtain and expensive (NCT04176016)
13 Jul 2023 Indium 111-radiolabelled OTSA 101 is still in phase I trials for Synovial-sarcoma (Refractory metastatic disease, Second-line therapy or greater) in Japan (IV, Injection) (NCT04176016)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com